Advances in histone demethylase KDM3A as a cancer therapeutic target

Jung Yoo, Yu Hyun Jeon, Ha Young Cho, Sang Wu Lee, Go Woon Kim, Dong Hoon Lee, So Hee Kwon

Research output: Contribution to journalArticle

Abstract

Lysine-specific histone demethylase 3 (KDM3) subfamily proteins are H3K9me2/me1 histone demethylases that promote gene expression. The KDM3 subfamily primarily consists of four proteins (KDM3A−D). All four proteins contain the catalytic Jumonji C domain (JmjC) at their C-termini, but whether KDM3C has demethylase activity is under debate. In addition, KDM3 proteins contain a zinc-finger domain for DNA binding and an LXXLL motif for interacting with nuclear receptors. Of the KDM3 proteins, KDM3A is especially deregulated or overexpressed in multiple cancers, making it a potential cancer therapeutic target. However, no KDM3A-selective inhibitors have been identified to date because of the lack of structural information. Uncovering the distinct physiological and pathological functions of KDM3A and their structure will give insight into the development of novel selective inhibitors. In this review, we focus on recent studies highlighting the oncogenic functions of KDM3A in cancer. We also discuss existing KDM3A-related inhibitors and review their potential as therapeutic agents for overcoming cancer.

Original languageEnglish
Article number1098
JournalCancers
Volume12
Issue number5
DOIs
Publication statusPublished - 2020 May

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Advances in histone demethylase KDM3A as a cancer therapeutic target'. Together they form a unique fingerprint.

  • Cite this

    Yoo, J., Jeon, Y. H., Cho, H. Y., Lee, S. W., Kim, G. W., Lee, D. H., & Kwon, S. H. (2020). Advances in histone demethylase KDM3A as a cancer therapeutic target. Cancers, 12(5), [1098]. https://doi.org/10.3390/cancers12051098